News coverage about Amyris (NASDAQ:AMRS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amyris earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.4743388653307 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

A number of brokerages have weighed in on AMRS. ValuEngine raised shares of Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Cowen and Company set a $4.00 price objective on shares of Amyris and gave the stock a “hold” rating in a report on Thursday, August 17th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Amyris in a report on Tuesday, September 26th. Finally, Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. Amyris currently has an average rating of “Hold” and a consensus price target of $20.69.

Amyris (NASDAQ AMRS) traded down $0.02 during trading hours on Monday, hitting $3.19. 310,922 shares of the stock were exchanged, compared to its average volume of 206,813. The company has a current ratio of 0.65, a quick ratio of 0.56 and a debt-to-equity ratio of -0.76.

Amyris (NASDAQ:AMRS) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.35). The firm had revenue of $25.68 million for the quarter, compared to the consensus estimate of $23.68 million. During the same period last year, the firm earned ($0.06) earnings per share. The business’s revenue for the quarter was up 167.5% compared to the same quarter last year. research analysts anticipate that Amyris will post -3.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-amyris-amrs-stock-price/1683927.html.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.